search
Back to results

A 4-month Intervention of Antioxidant Supplementation in Overweight Children

Primary Purpose

Metabolic Syndrome

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine
Sponsored by
Swiss Federal Institute of Technology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Metabolic Syndrome focused on measuring antioxidant supplementation, childhood obesity, hepcidin, iron status, oxidative stress, inflammation

Eligibility Criteria

10 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • age between 10 to 18 years old
  • BMI over the 85th percentile for age and sex

Exclusion Criteria:

  • history of nephrolithiasis
  • history of bleeding disorder
  • smoking
  • type 2 diabetes
  • NAFLD
  • Asthma

Sites / Locations

  • Swiss Federal Institute of Technology , Laboratory of Human Nutrition

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Antioxidant Group

Placebo Group

Arm Description

500mg Vitamin C 400 I.E. Vitamin E 50 mcg Selenium

identical appearing placebo supplements

Outcomes

Primary Outcome Measures

oxidative markers (isoprostanes)
inflammatory parameters

Secondary Outcome Measures

Full Information

First Posted
March 15, 2011
Last Updated
June 18, 2012
Sponsor
Swiss Federal Institute of Technology
search

1. Study Identification

Unique Protocol Identification Number
NCT01316081
Brief Title
A 4-month Intervention of Antioxidant Supplementation in Overweight Children
Official Title
A 4-month, Randomized, Placebo-controlled, Double-blind Intervention of Antioxidant Supplementation in Overweight Children Enrolled in an Outpatient Weight-loss Program: Effects on Oxidative and Inflammatory Markers, Hepcidin, Iron Status, and Components of the Metabolic Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
June 2012
Overall Recruitment Status
Completed
Study Start Date
March 2011 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
June 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Swiss Federal Institute of Technology

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In obese children, low antioxidant vitamin intake and reduced antioxidant capacity are common. Weight reduction reduces subclinical inflammation in obese subjects, and, similarly, antioxidant vitamins have been shown to reduce the expression of proinflammatory cytokines. Moreover, antioxidants reduce oxidative stress which influences endothelial function and might play a crucial role in the pathogenesis of obesity-related disorders. Furthermore, overweight children and adults have a markedly increased risk for iron deficiency. The mechanism linking obesity with iron deficiency is unclear. Growing evidence suggests that the elevated inflammatory status associated with obesity increases circulating hepcidin and this contributes to iron deficiency. Weight reduction has been shown to be associated with reduced inflammation and serum hepcidin concentrations, and an improved functional iron state. Thus, reducing inflammation in obese children may improve iron metabolism and reduce their risk of iron deficiency. Therefore, positive effects on subclinical inflammation, hepcidin/iron status and metabolic risk factors in obese children during weight loss may be enhanced by supplementation with antioxidants. The aim of the present study is to investigate the effect of 4-month antioxidant supplementation on subclinical inflammation, hepcidin, iron status and components of the metabolic syndrome in overweight children undergoing an outpatient weight-loss program. Our hypotheses are: 1. During an outpatient weight loss program, antioxidant supplementation will reduce oxidative and inflammatory stress associated with obesity to a greater extent than weight loss alone. 2. This will have two effects, compared to weight loss alone: a.It will reduce circulating hepcidin concentrations, and improve iron status. b.It will improve metabolic and cardiovascular risk factors. Subjects The investigators plan to enroll 50 children who are participants in outpatient weight-loss programs in the German part of Switzerland. Enrollment will be done with the agreement and assistance of the physician supervising the weight-loss program, and the timing of the study measurements will be incorporated within the existing program schedule. It is anticipated that the baseline blood sample for this study will be obtained from the regular baseline venipuncture for the weight-loss study. Criteria for participation include age between 10 to 18 years and a BMI over the 85th percentile for age and sex. Exclusion criteria include major medical illnesses, including gastrointestinal, inflammatory, bleeding and/or endocrine disorders, a history of nephrolithiasis, unusual dietary habits (e.g. vegetarianism), major food allergies or intolerances (lactose, gluten), smoking, and use of chronic medications or vitamin/mineral antioxidant supplements. Study design The study will be a double-blind, randomized, placebo-controlled intervention trial. Children will be randomly assigned to one of two groups: antioxidant (AO) or placebo (P) supplement. If it is necessary to enroll children from different weight-loss programs, then randomization will be stratified by program. During the 4-month weight loss period, the AO group will consume oral supplements of ascorbic acid (500mg), alpha tocopherol (400 IU), and 50 µg selenium (all from Burgerstein Vitamins, Rapperswil-Jona, Switzerland) each evening with diner, whereas the P group will consume identical-appearing placebo supplements.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome
Keywords
antioxidant supplementation, childhood obesity, hepcidin, iron status, oxidative stress, inflammation

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
45 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Antioxidant Group
Arm Type
Experimental
Arm Description
500mg Vitamin C 400 I.E. Vitamin E 50 mcg Selenium
Arm Title
Placebo Group
Arm Type
Placebo Comparator
Arm Description
identical appearing placebo supplements
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine
Other Intervention Name(s)
Burgerstein Vitamin C retard 500mg SWISSMEDIC Nr. 44259028, Burgerstein Vitamin E 400 I.E. SWISSMEDIC Nr. 44562014, Burgerstein Selenvital 50µg
Intervention Description
Vitamin C: 500mg Vitamin E: 400 I.U. Selenium: 50mcg Placebo Supplements: identical appearing tablets
Primary Outcome Measure Information:
Title
oxidative markers (isoprostanes)
Time Frame
blood sample after 4 months
Title
inflammatory parameters
Time Frame
blood sample after 4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age between 10 to 18 years old BMI over the 85th percentile for age and sex Exclusion Criteria: history of nephrolithiasis history of bleeding disorder smoking type 2 diabetes NAFLD Asthma
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael B Zimmermann, Prof
Organizational Affiliation
ETH Zurich
Official's Role
Principal Investigator
Facility Information:
Facility Name
Swiss Federal Institute of Technology , Laboratory of Human Nutrition
City
Zürich
ZIP/Postal Code
8092
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
24353344
Citation
Murer SB, Aeberli I, Braegger CP, Gittermann M, Hersberger M, Leonard SW, Taylor AW, Traber MG, Zimmermann MB. Antioxidant supplements reduced oxidative stress and stabilized liver function tests but did not reduce inflammation in a randomized controlled trial in obese children and adolescents. J Nutr. 2014 Feb;144(2):193-201. doi: 10.3945/jn.113.185561. Epub 2013 Dec 18.
Results Reference
derived

Learn more about this trial

A 4-month Intervention of Antioxidant Supplementation in Overweight Children

We'll reach out to this number within 24 hrs